Cost-Effectiveness Analysis of Canagliflozin 300  mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States

ConclusionThese results suggest that canagliflozin 300  mg is likely to provide better health outcomes at a lower overall cost than dapagliflozin 10 mg in patients with T2DM inadequately controlled with metformin from the perspective of the United States health care system.FundingJanssen Scientific Affairs, LLC and Janssen Global Services, LLC.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research